Abstract

The NIH and Vical Inc are developing an intramuscular needle-free DNA vaccine containing plasmids encoding the envelope glycoprotein of Ebola virus (EBOV) from the Sudan and Zaire strains, and the nucleoprotein of EBOV Zaire strain. A phase I clinical trial demonstrated a good safety profile, with most adverse events limited to the site of injection and largely attributable to the delivery.

Authors

Dery M, Bausch DG

Institution

Tulane University Health Sciences Center, Department of Medicine, Infectious Diseases Section, 1430 Tulane Ave SL-87, New Orleans, LA 70112-2699, USA. madery@tulane.edu

Source

Current opinion in molecular therapeutics 10:3 2008 Jun pg 285-93

MeSH

Clinical Trials as Topic
Drug Evaluation, Preclinical
Ebola Vaccines
Hemorrhagic Fever, Ebola
Humans
Structure-Activity Relationship
Vaccines, DNA

Pub Type(s)

Journal Article

Language

eng

PubMed ID

18535936